

Subject index

A

- Acantholytic variant, squamous cell carcinoma, 38, 40, 41
Acanthosis nigricans, 189
Acinic cell carcinoma, 45
Acquired melanocytic naevus, 331, 332
Adenocarcinoma in situ, 232, 272, 273, 275, 276
Adenocarcinoma of Skene gland origin, 324
Adenocarcinoma of the rete ovarii, 180
Adenocarcinoma with spindle cell metaplasia, 38
Adenocystic basal cell carcinoma, 44
Adenofibroma, 122, 124, 125, 127, 130, 196, 209, 245, 248, 284, 285
Adenohibernoma, 103
Adenoid basal carcinoma, 267, 277-279, 301
Adenoid cystic carcinoma, 28, 44, 57, 86, 182, 184, 185, 228, 267, 277-279, 301, 321-323
Adenolipoma, 94, 103
Adenoma malignum, 273
Adenoma of minor vestibular glands, 324
Adenoma of the rete ovarii, 181
Adenomatoid tumour, 197, 199, 211, 243, 244, 310
Adenomatous hyperplasia of the rete ovarii, 181
Adenomyoepithelial adenosis, 82, 86, 87
Adenomyoepithelioma, 44, 46, 82, 86, 87
Adenomyoma, 134, 188, 215, 235, 245, 249, 273, 284-286, 321, 323
Adenosarcoma, 130, 133, 210, 212, 215, 244-248, 281, 282, 284-286, 306, 307
Adenosis, 78, 81-83, 85, 87, 104, 295, 297, 299, 300
Adenosis with apocrine metaplasia, 82
Adenosquamous carcinoma, 39-41, 130, 174, 266, 273, 277, 278, 301, 321, 322
Adrenocortical carcinoma, 351, 352, 354
Adult granulosa cell tumour, 131, 146
AFP, *see* alpha-fetoprotein
Aggressive angiomyxoma, 305, 329
Aggressive T-cell leukaemia, 361
Akt, 231, 357
Alpha lactalbumin, 41, 43
Alpha-fetoprotein, 138, 155, 156, 165-168, 184, 207, 246, 309
Alveolar rhabdomyosarcoma, 215, 244, 282
Alveolar soft part sarcoma, 215, 244, 280-282, 304, 326, 327
Alveolar variant, lobular carcinoma, 24, 32
Amenorrhoea, 154, 157, 175, 190
Amylase, 45
Androblastoma, 153
Androgen insensitivity syndrome, 157
Androgen receptor gene, 112, 154
Angiogenesis, 22
Angiolipoma, 93
Angiomyofibroblastoma, 327, 329, 330
Angiosarcoma, 40, 89, 91, 94-96, 175, 188, 244, 280, 282, 304
Apocrine adenoma, 85
Apocrine adenosis, 82
Apocrine carcinoma, 36, 37, 47, 71
Apocrine cell, 36, 37, 47, 65
APPBP2, 51
Argyrophilia, 33, 80
A-T complementation, 361
Ataxia telangiectasia, 27, 342, 350, 353, 361-363
ATM *see* Ataxia telangiectasia
Atypical adenosis, 299, 300
Atypical carcinoid, 277, 279
Atypical columnar change, 66
Atypical cystic lobules, 63, 66
Atypical ductal hyperplasia, 20, 63, 64, 66, 78
Atypical hyperplasia, 63, 84, 136, 210, 221, 222, 228, 229, 232, 359
Atypical intraductal hyperplasia, 66, 78
Atypical leiomyoma, 236, 241
Atypical lobular hyperplasia, 60
Atypical lobules, type A, 66
Atypical medullary carcinoma, 28, 338
Atypical melanocytic naevus of the genital type, 332
Atypical papilloma, 78
Atypical polypoid adenomyoma, 249, 285, 286
Atypical proliferative serous tumour, 121
Atypical vulvar naevus, 332
Aurora-A, 51

B

- B72.3 (TAG-72) antibody, 119, 131, 138, 187
Bannayan-Riley-Ruvalcaba syndrome, 357
BARD1, 342
Barr bodies, 171
Bartholin gland adenoma, 323
Bartholin gland carcinoma, 322
Bartholin gland nodular hyperplasia, 323
Bartholin gland tumour, 321, 322
Basal cell carcinoma, 151, 174, 175, 184, 185, 316, 318, 319
Basal cell tumour, 182, 184, 185
Basaloid carcinoma, 267, 316
Basaloid squamous cell carcinoma, 267, 278, 279, 317
BASC, *see* BRCA1-associated surveillance complex
Bcl-2, 58, 92, 108, 109, 250
BEK, 51
Benign mesothelioma, 199
Benign metastasizing leiomyoma, 237, 242
Benign mixed epithelial tumour, 144
Benign mixed tumour, 85, 306, 307
Benign peripheral nerve sheath tumour, 92, 94
Benign sclerosing ductal proliferation, 83
Beta-catenin, 131
Bethesda Criteria, 358
 β -hCG, 22, 164, 165, 167, 168, 207, 250, 251, 252
Bilateral breast carcinoma, 23, 48

Biphasic teratomas, 168
 BLM, 341, 342
 Bloom syndrome, 349
 Blue naevus, 287, 288, 308, 309, 331, 332
 Blunt duct adenosis, 82
 BMPR1A, type 1A receptor of bone morphogenetic proteins (BMP) 357
 Body mass index, 111
 Borderline Brenner tumour, 140, 142
 Borderline clear cell adenofibromas with intraepithelial carcinoma, 139
 Borderline clear cell adenofibromatous tumour, 139
 Borderline mixed epithelial tumour, 144
 Bowenoid papulosis, 319, 320
 BRAF, 120
 BRCA1, 14, 20, 29, 53-56, 118, 120, 202, 207, 208, 337-348, 350, 351, 353, 354, 362
 BRCA1-associated genome surveillance complex, 341, 342
 BRCA2, 20, 29, 53-56, 112, 118, 133, 207, 208, 337-351, 354
 Brenner tumour, 140-145, 172, 190, 196, 212
 Brenner tumour of low malignant potential, 142
 BRUSH-1, 112
 BTAK /aurora2 /STK15, centrosome-associated serine/threonine kinase, 51
 Burkitt lymphoma, 107, 108, 191, 196

C

CA125, 109, 119, 130, 138, 141, 180, 181, 184, 202, 272, 322, 340, 341, 347, 348
 CA19-9, carbohydrate antigen 19-9, 109
 Call-Exner bodies, 131, 145, 147, 177
 Calponin, 45, 75, 86, 91, 243
 Calretinin, 119, 147, 157, 180, 185, 198, 213, 244, 255, 275
 Cambium layer, 230, 283, 297, 302, 303
 Carcinoembryonic antigen, 106, 138, 164, 187, 224, 272, 276, 322, 332
 Carcinofibroma, 245, 248
 Carcinoid, 171, 172, 196, 277, 279, 301
 Carcinoid syndrome, 172
 Carcinoma adenoides cysticum, 44
 Carcinoma of the male breast, 110
 Carcinoma with choriocarcinomatous features, 22
 Carcinoma with melanotic features, 22

Carcinoma with osteoclastic giant cells, 21
 Carcinosarcoma, 37, 40, 127, 133, 174, 230, 236, 245-247, 255, 284, 285, 306, 347
 CCND1, 51, 59, 72, 73
 CD10, 108, 109, 135, 180, 187, 213, 233, 235, 240, 243, 248, 275
 CD30, 108, 166, 167
 CD31, 91, 95, 269, 282
 CD34, 91, 92, 95, 269, 282, 307, 327
 CD68, 22, 91, 98, 161, 192, 196, 311
 CD99, 92, 147, 157, 174, 183, 188, 234, 255, 307, 309, 334
 CD117, 164
 Cdc25A, 354
 Cdc25C, 354
 CDH1, 53
 CDKN2A, 52
 CEA, 164, 341, 348
 Cellular angiofibroma, 327, 329, 330
 Cellular fibroma, 149-151
 Cellular leiomyoma, 235, 236, 239, 240
 Cellular variant, blue naevus, 308, 309
 Central papilloma, 76-78
 C-erbB, 250, 266
 Cervical intraepithelial neoplasia, 63, 262, 264-273, 276, 279, 294, 295, 319
 Charcot-Böttcher filaments, 157
 CHEK2, 350, 351, 353, 354, 362
 Chloroacetate esterase, 196, 311
 Chloroma, 192, 196, 311
 Chondrolipoma, 94
 Choriocarcinoma, 168, 186, 210, 250-252, 311
 Chorionic gonadotrophin, 22
 Chromogranin A, 30
 Chromosomal double-strand breaks, 342
 Chymotrypsin, 45
 Ciliated cell variant, endometrioid adenocarcinoma, 221, 224
 CIN, *see* Cervical intraepithelial neoplasia
 c-Jun, 352
 CK 5,6, 61, 92
 CK14, 86
 CK34BE12, 38, 61, 65
 CK5, 38, 65, 86
 CK5/6, 38
 CK7, 38, 226, 227
 C-kit, 164
 Clear cell adenocarcinofibroma, 137

Clear cell adenocarcinoma, 137-139, 188, 195, 206, 207, 212, 221, 223-226, 272, 274, 276, 297-300
 Clear cell adenofibroma, 137, 139
 Clear cell adenofibromatous tumour of borderline malignancy, 139
 Clear cell carcinoma, 46, 137, 138, 160, 166, 196, 212, 228, 339
 Clear cell cystadenofibroma, 137
 Clear cell cystadenoma, 137
 Clear cell hidradenoma, 46, 325
 Clear cell leiomyoma, 241
 Clinging carcinoma, 63, 66
 c-Myc, 72, 266
 Coagulative necrosis, 164
 Cobblestone-like papules, 356
 COL1A1/PDGFB, 327
 Collagenous spherulosis, 44, 60, 78
 Colloid carcinoma, 30, 272
 Columnar cell mucinous carcinoma, 30, 31
 Complete hydatidiform mole, 252-254
 Complex (adenomatous) hyperplasia of the endometrium, 229
 Complex sclerosing lesion, 27, 81-83
 Condylomatous squamous cell carcinoma, 267
 Congenital melanocytic naevus, 331, 332
 Cotyledonoid dissecting leiomyoma, 216, 241
 Cowden syndrome, 232, 355
 CSE1L/CAS, 51
 CTNNB1 (beta-catenin), 131
 Cushing syndrome, 160, 175
 Cyclin D1, 51, 73, 338
 Cylindromatous carcinoma, 44
 CYP24, 51
 Cystadenocarcinoma, 145
 Cystic lymphangioma, 199
 Cytokeratin 7, 25, 33, 45, 106, 109, 119, 129, 141, 147, 156, 195, 226, 268, 275
 Cytokeratin 14, 45
 Cytokeratin 20, 33, 119, 143, 187, 213, 226, 341, 348,
 Cytokeratin 34betaE12, 86, 187, 213
 Cytokeratin AE1/AE3, 21, 47, 119, 161
 Cytokeratin CAM5.2, 21, 119, 187
 Cytotrophoblast, 164, 167, 168, 186, 251, 252

D

DAM1, 50

- DCIS, *see* Ductal carcinoma in situ 20, 25, 26, 28, 32, 33, 35, 60, 61, 63-73, 75, 77-81, 101, 106, 112, 338, 346, 347, 356
- Deciduoid mesothelioma, 197
- Deep angiomyxoma, 304, 305, 327, 329, 330
- Dermatofibrosarcoma protuberans, 327
- Dermoid cyst, 127, 129, 143, 163, 169-175, 188, 196, 215, 287, 288, 310
- DES, 274, 297, 298, 299
- Desmoid tumour, 92
- Desmoplastic small round cell tumour, 197, 200
- Diethylstilbestrol, 274, 297
- Diffuse angioma, 89
- Diffuse large B-cell lymphoma, 108
- Diffuse leiomyomatosis, 237, 241
- Diffuse malignant mesothelioma, 197, 198
- Diffuse peritoneal leiomyomatosis, 200
- DIN, 63, 64, 66, 67
- Dissecting leiomyoma, 241
- Disseminated peritoneal adenomucinosis, 128
- DNA ploidy, 53, 54
- Ductal adenoma, 77, 85
- Ductal carcinoma in situ, 20, 25, 26, 28, 32, 33, 35, 40, 44, 58, 60, 61, 63-75, 77-81, 101, 106, 112, 338, 346, 347, 356
- Dysgerminoma, 138, 163-166, 168, 176-179, 191, 196, 340
- Dyskeratosis, 270
- Dysplasia, 254, 269, 284, 294, 295, 319, 345
- Dysplasia/carcinoma-in-situ, 269
- Dysplastic melanocytic naevus, 331, 333
- E**
- E6, 262, 265, 318
- E7, 262, 263
- Early invasive adenocarcinoma, 272, 275
- Early invasive squamous cell carcinoma, 268
- EBV, *see* Epstein-Barr Virus
- E-cadherin, 24, 25, 29, 33, 53, 61, 62, 65, 71, 72, 112, 252
- Ectopic decidua, 189, 198
- EGFR, 27, 50, 58, 202, 250
- EIN, 231, 232
- EMA, *see* Epithelial membrane antigen
- Embryoid bodies, 167
- Embryonal carcinoma, 163, 166-168
- Embryonal rhabdomyosarcoma, 97, 211, 215, 248, 281, 302, 303, 326
- EMK, 112
- Enchondromatosis, 149
- Encysted papillary carcinoma, 79
- Endocervical polyp, 276, 277
- Endocervical-like borderline tumour, 126, 127
- Endocrine carcinoma, 32
- Endodermal sinus tumour, 165, 288, 309, 333
- Endometrial hyperplasia, 131, 132, 137, 146, 152, 187, 221, 222, 225, 228, 229, 231, 232, 359
- Endometrial polyp, 209, 230, 245, 246, 249
- Endometrial stromal nodule, 233-236
- Endometrial stromal sarcoma, 149, 190, 196, 216, 233, 234, 245, 247, 281, 309
- Endometrioid adenocarcinoma, 130, 143, 206, 207, 212, 221-226, 230, 232, 249, 272-275, 297, 300
- Endometrioid borderline tumour, 130, 135, 136
- Endometrioid polyp, 209
- Endometrioid stromal sarcoma, 130, 134, 135, 147, 215, 235, 280, 281, 302, 303
- Endometrioid tumour of borderline malignancy, 135
- Endometrioid tumour of low malignant potential, 135
- Endometriosis, 127, 130-137, 143, 145, 180, 190, 195, 200, 210, 212, 215, 235, 281, 300, 303, 324
- Endometriosis with smooth muscle metaplasia, 215
- Endometroid yolk sac tumour, 166
- Endomyometriosis, 215
- Endosalpingiosis, 123, 210
- Endosalpinx, 340, 347
- Ependymoma, 171, 174, 212, 213
- Epidermoid cyst, 144, 175
- Epithelial membrane antigen, 21, 22, 43, 45, 91, 119, 131, 138, 147, 154, 156, 157, 161, 180, 182, 187, 200, 213, 255, 275, 332,
- Epithelioid leiomyoma, 236, 241
- Epithelioid leiomyosarcoma, 238, 241, 252, 280, 281
- Epithelioid trophoblastic tumour, 251, 252
- Epitheliosis, 65, 104
- Epstein-Barr virus, 17, 29, 108, 268, 311
- ERB receptor, 58
- ERBB2, 23, 25, 27, 29, 35, 48, 51, 53, 58-60, 66, 72, 73, 106, 112, 202, 338, 341, 346
- ERBB3, 51, 202
- ERBB4, 51, 202
- Erosive adenomatosis, 104
- Ewing tumour, 174, 200, 211, 244, 255, 309, 333, 334
- EWS/FLI1, 174, 309, 334
- EWS-WT1, 200, 201
- Exaggerated placental site, 254
- Exonic splicing enhancer, 350
- Extranodal marginal-zone B-cell lymphoma, 108
- F**
- Factor VIII protein, 91
- FANCA, 52
- FANCD1, 346, 350
- Fanconi anaemia, 342, 349, 350
- Fanconi anaemia D2 protein, 342
- Fetiform teratoma, 163, 170
- FGFR1, 50, 59
- FGFR2, 51
- FHIT, 27, 52, 265
- Fibroadenoma, 30, 81, 84, 90, 98, 99, 253
- Fibrocystic disease, 355, 356
- Fibroepithelial polyp, 271, 297, 302, 303, 320, 321, 329, 330
- Fibroma, 134, 135, 149-153, 158, 187, 190, 215, 325
- Fibromas of the oral mucosa, 356
- Fibromatosis, 39, 40, 88, 92, 190
- Fibrosarcoma, 40, 101, 135, 151, 175, 188, 304
- Fibrosis mammae virilis, 110
- Fibrothecomatous stroma, 147, 148
- Flat epithelial atypia, 26, 63, 65, 66
- FLG, 50
- Florid papillomatosis, 104
- Follicular lymphoma, 107, 109, 191
- Folliculome lipidique, 157
- Fragile histidine triad, 265

G

GADD45, 343, 353
GCDFP-15, 25, 33, 36, 37, 44, 45
Gelatinous carcinoma, 30
Genital rhabdomyoma, 282, 304
Gestational choriocarcinoma, 168, 182, 186, 210, 251, 334
Gestational trophoblastic disease, 210, 250
GFAP, 86, 174
Glandular dysplasia, 265, 276
Glassy cell carcinoma, 228, 277, 279
Glioblastoma, 171, 174
Gliomatosis peritonei, 170
Glomus tumour, 171, 175, 283, 330
Glycogen-rich carcinoma, 46
Goblet cell, 124-127, 156, 173, 195, 206, 224, 272
Goldenhar syndrome, 149
Gonadoblastoma, 163, 164, 167, 176-179
Grading of invasive carcinoma, 18
Granular cell tumour, 36, 37, 94, 283, 327, 330
Granulocytic sarcoma, 109, 191, 192, 196, 311, 334
Granulosa cell tumour, 131, 134, 145-151, 159, 160, 183, 196, 215
Granulosa-stromal cell tumours, 160
GRB7, 53
Gynaecomastia, 90, 91, 110, 111
Gynandroblastoma, 158, 159

H

5-HIAA, 5-hydroxyindoleacetic acid, 173
Haemangioblastoma, 94
Haemangioma, 89, 94, 244, 283, 330
Haemangiomas, 149, 357
Haemangiopericytoma, 90, 244
Haemangiosarcoma, 94
Haematoperitoneum, 186
Haematosalpinx, 206
Haemorrhagic cellular leiomyoma, 240
HAIR-AN syndrome, 189
Hamartoma, 98, 100, 355, 357
Hamartomatous polyps of the colon, 356
HBME1, 244
H-caldesmon, 234, 235, 240, 243
Hepatocellular carcinoma, 184, 353
Hepatoid carcinoma, 182, 184
Hepatoid yolk sac tumour, 165, 184

HER2, 51, 58
Herceptin, 58, 73
Hereditary breast-ovarian cancer syndrome, 208
Hereditary colorectal endometrial cancer syndrome, 358
Hereditary defective mismatch repair syndrome, 358
Hereditary fallopian tube carcinoma, 340, 347
Hereditary nonpolyposis colon cancer syndrome, 53, 118, 132, 232, 337, 358-360
Hibernoma, 94
HIC1, 52
Hilus cell tumour, 161
Hirsutism, 154, 157, 190
Histiocytoid carcinoma, 46
HIV, 262, 269, 319, 320
HMB45, 106, 109
HMGIC, 230, 242
HMGiY, 230, 242
HNPPC, *see* Hereditary non-polyposis colon cancer
Homunculus, 170
HPV, *see* Human papilloma virus
hRad50-hMre11-NBS1p95 (R/M/N) complex, 342
HRAS1, 343
Human papillomavirus, 226, 227, 262, 265-271, 293, 295, 296, 311, 316-321
Hydatidiform mole, 182, 186, 210, 250-252, 254
Hydrosalpinx, 206
Hypercalcaemia, 137, 138, 148, 182
Hyperoestrinism, 146, 221, 222, 225
Hyperplasia of the usual type, 65
Hyperplasias without atypia of the endometrium 229
Hyperreactio luteinalis, 189

I

IGF2R, 52
IGF-binding proteins, 16
Immature teratoma, 166, 169-171, 174, 188
Infiltrating ductal carcinoma, 19, 20, 22, 23, 28, 31
Infiltrating epitheliosis, 83
Infiltrating myoeipithelioma, 88
Infiltrating syringomatous adenoma, 39, 105
Inflammatory carcinoma, 47

Inflammatory myofibroblastic tumour, 92, 93
Inflammatory pseudotumour, 93
Inhibin, 131, 135, 138, 147, 148, 150, 151, 154, 156, 157, 159-161, 174, 180, 182, 187, 188, 213, 234, 243, 255
Insulin-growth factor-I, 16
Intercellular adhesion molecule-1, 29
Intestinal-type borderline tumour, 127, 129
Intracystic papillary carcinoma, 34, 79, 80
Intraductal carcinoma, 27, 46, 67, 105, 106
Intraductal hyperplasia, 65
Intraductal papillary carcinoma, 76, 78, 79, 80
Intraductal papillary neoplasms, 76
Intraductal papilloma, 76, 78, 81, 85
Intraductal proliferative lesions, 63, 64, 77
Intravenous leiomyomatosis, 216, 235, 237, 241, 242
Invasive breast carcinoma, 13, 18, 58, 63, 64, 71, 78, 96, 112, 362
Invasive cribriform carcinoma, 22, 27, 28
Invasive ductal carcinoma, 18-20, 35, 57, 64, 72, 73, 353
Invasive ductal carcinoma, no specific type, 19
Invasive ductal carcinoma, not otherwise specified, 19
Invasive hydatidiform mole, 254
Invasive lobular carcinoma, 20, 23, 32, 36, 42, 49, 51, 61, 62, 338, 346
Invasive micropapillary carcinoma, 35
Invasive papillary carcinoma, 34, 35
Inverted follicular keratosis, 321

J

JAZF1, JAZ1, 234
Juvenile carcinoma, 42
Juvenile fibroadenoma, 99
Juvenile granulosa cell tumour, 146, 148, 174, 182

K

Keratinizing type squamous cell carcinoma, 266, 267, 316, 317
Keratoacanthoma, 317, 321
Ki-67, 57, 270, 272

- Koilocytosis, 267, 270, 271, 294, 295, 296, 320, 321
- KRAS, 120, 125, 129, 145, 202, 231, 281
- Krukenberg tumour, 153, 190, 193-196
- L**
- Lactating adenoma, 84
- Laminin, 27, 28, 44, 53, 81, 82, 278
- Large cell keratinizing squamous cell carcinoma, 38
- Large cell neuroendocrine carcinoma, 33, 184, 279
- Large duct papilloma, 76
- LCIS, *see* Lobular carcinoma in situ
- Leiomyoblastoma, 238, 241
- Leiomyoma, 98, 215, 216, 233-237, 239-242, 244, 256, 281, 282, 304, 327, 330, 355
- Leiomyomatosis peritonealis disseminata, 200
- Leiomyosarcoma, 98, 175, 196, 211, 215, 233, 236-240, 245, 280, 281, 283, 302, 303, 305, 326, 330
- Leukaemia, 49, 109, 191, 192, 196, 211, 289, 311, 334, 351, 361
- Leukoplakia, 264
- Leuprolide, 238
- Leydig cell tumour, 131, 154, 158, 160, 161
- Leydig cell tumour, non-hilar type, 161
- Lichen sclerosus, 316
- Li-Fraumeni syndrome, 65, 67, 351, 352, 354
- LIN, *see* Lobular intraepithelial neoplasia
- Lipid cell tumour, 160
- Lipid secreting carcinoma, 41
- Lipid-rich carcinoma, 41
- Lipofuscin, 22, 154, 160, 161
- Lipoleiomyoma, 237, 241, 244
- Lipoma, 93, 94, 103, 175, 244, 283, 330
- Lipomatosis, 357
- Liposarcoma, 40, 96, 97, 101, 211, 215, 244, 246, 282, 326, 327, 329
- Lobular carcinoma in situ, 23-25, 53, 60, 61, 74, 338, 346
- Lobular intraepithelial neoplasia, 60-62, 81, 101, 106, 112
- Lobular neoplasia, 20, 26, 60, 71, 75, 338
- Louis-Bar Syndrome, 361
- Low grade adenosquamous carcinoma, 39, 105
- Luteinized thecoma, 149, 150, 158
- Luteoma of pregnancy, 160, 188, 189, 196
- Lymphangiosarcoma, 94, 188
- Lymphoblastic lymphoma, 107
- Lymphoedema, 95, 96, 263
- Lymphoepithelioma, 29, 207, 266-268
- Lymphoepithelioma-like carcinoma, 207, 267, 268
- Lymphoma, 108, 191, 289, 310
- Lynch syndrome, 358
- Lysozyme, 45, 196, 311
- M**
- M6P/IGF2R, 52
- Macrocephaly, 355, 357
- Maffucci syndrome, 149, 151
- Major duct papilloma, 76
- Malignant Brenner tumour, 140, 142
- Malignant fibrous histiocytoma, 96, 175, 244, 282, 304
- Malignant lymphoma, 107, 109, 112, 183, 191, 192, 211, 256, 311, 334
- Malignant melanoma, 22, 23, 106, 109, 112, 160, 171, 196, 287, 308, 317, 331-334, 353
- Malignant mesodermal mixed tumour, 133, 245, 306
- Malignant mesothelioma, 182, 185, 197-199
- Malignant mixed epithelial tumour, 144
- Malignant müllerian mixed tumour, 130, 133, 149, 156, 188, 210, 245, 284, 306
- Malignant myoepithelioma, 86, 88
- Malignant peripheral nerve sheath tumour, 188, 244, 280-282, 304
- Malignant pigmented neuroectodermal tumour of infancy, 244
- Malignant rhabdoid tumour, 244, 327
- Malignant struma, 171, 172
- Malignant sweat gland tumour, 324
- MALT lymphoma, 108, 109
- Mammary hamartoma, 103
- Mammary osteogenic sarcoma, 97
- Masculinization, 189
- Maspin, 86
- Massive ovarian oedema, 190
- Matrix producing carcinoma, 37, 40
- Mature cystic teratoma, 163, 170, 174, 287, 288, 310
- Mature teratoma, 168-171, 174, 175, 215, 288
- MDM2, 53, 250, 352, 353
- Medullary carcinoma, 20, 28, 34, 57, 109, 338
- Medulloblastoma, 174
- Medulloepithelioma, 174
- Megencephaly, 355
- Meigs syndrome, 151, 172, 215
- Melan A, 188, 332
- Melanocytic naevus, 171, 175, 308, 309, 331, 333
- Melanocytic tumours, 175, 308, 331
- Melanotic paraganglioma, 255
- Menometrorrhagia, 154, 157, 221
- Mental retardation, 355
- Merkel cell tumour, 333
- Mesonephric adenocarcinoma, 272, 274, 275, 284, 297, 300
- Metaplastic carcinoma, 37, 39-41, 85, 97, 133, 245, 246, 284, 306
- Metaplastic papillary tumour, 209
- Metastasizing leiomyoma, 242
- Metastatic hydatidiform mole, 254
- MIB-1, 57
- MIC2, 174, 183
- Microglandular adenosis, 27, 82
- Microinvasive carcinoma, 49, 74, 75, 269, 316
- Microinvasive squamous cell carcinoma, 268, 269
- Micropapillary pattern, 26, 70, 123
- Micropapillomatosis labialis, 320
- Microsatellite instability, 53, 131, 132, 231, 232, 358, 360
- Microscopic papilloma, 77
- Minimal deviation adenocarcinoma, 265, 272, 273, 285, 286
- Mismatch repair, 53, 132, 232, 337, 358, 360
- Mitotically active leiomyoma, 240
- Mixed ductal-lobular carcinoma, 25
- Mixed endometrial stromal and smooth muscle tumour, 235, 242
- Mixed epithelial tumour, 143, 144
- Mixed germ cell-sex cord-stromal tumour, 176, 178, 179
- Mixed gonadal dysgenesis, 177
- Mixed type carcinoma, 21, 24, 27
- MLH1, 53, 118, 131, 132, 337, 342, 358-361
- MLH3, 359, 360
- MMR, 358, 360
- Monoclonality, 265
- Monodermal teratoma, 171, 175

MPNST, *see* Malignant peripheral nerve sheath tumour
MRE11, 341
MSH2, 53, 118, 132, 337, 342, 358-361
MSH6, 53, 337, 342, 358-361
MSI, 53, 359-361
MSI-H, 360, 361
Mucin producing carcinoma, 30
Mucinous adenocarcinoma, 124, 206, 212, 221, 224, 272, 273, 297, 300
Mucinous borderline tumour, 124-126, 128, 145, 193
Mucinous borderline tumour, intestinal type, 125
Mucinous carcinoid, 171, 173, 195
Mucinous carcinoma, 30, 31, 34, 35, 57, 80, 124-126, 128, 195, 206, 226, 339
Mucinous cystadenocarcinofibroma, 124
Mucinous cystadenocarcinoma, 30-32, 145
Mucinous cystadenoma, 124-127, 129, 143, 156, 175, 209, 212
Mucinous cystic tumours with mural nodules, 127
Mucinous tumour of borderline malignancy, endocervical-like, 126
Mucinous tumour of borderline malignancy, intestinal type, 125
Mucinous tumour of low malignant potential, endocervical-like, 126
Mucinous tumour of low malignant potential, intestinal type, 125
Mucocoele-like lesion, 31
Mucoepidermoid carcinoma, 39, 277
Mucoid carcinoma, 30, 42
Mucosal/acral lentiginous melanoma, 331
Muir-Torre syndrome, 132
MUL, 51
Müllerian papilloma, 276, 300
Multicystic mesothelioma, 197, 198
Multilocular peritoneal inclusion cyst, 198
Multinodular goitre, 356
Multinucleated giant cells, 92, 99, 207
Multiple facial trichilemmomas, 356
Multiple hamartoma syndrome, 355
MutL homologue 1, 359
MutL homologue 3, 359
MutS homologue 2, 359
MutS homologue 6, 359
Myc, 250, 266
Myoepithelial carcinoma, 40, 86, 88, 92

Myoepitheliosis, 86
Myofibroblastoma, 91
Myoglobin, 246, 302
Myoid hamartoma, 103
Myxoid leiomyoma, 236, 241
Myxoid leiomyosarcoma, 238
Myxoma, 182, 187, 244

N

NCOA3 (AIB1), 51, 343, 350
Neuroblastoma, 51, 174, 334
Neuroendocrine carcinoma, 30, 43, 184, 279, 333
Neuroendocrine tumours, 32, 144, 277, 279
Neurofibroma, 94, 329, 330
Neuron-specific enolase, 200, 255
Nevoid basal cell carcinoma syndrome, 151
NFKB / NF-kappaB, 352, 362
Nipple adenoma, 81, 104
Nipple discharge, 68, 74, 76, 77, 85, 92, 97, 101, 112
Nipple duct adenoma, 104
Nodular adenosis with apocrine metaplasia, 85
Nodular hidradenoma, 324, 325
Nodular melanoma, 331
Nodular theca-lutein hyperplasia of pregnancy, 188
Non-encapsulated sclerosing lesion, 83
Non-gestational choriocarcinoma, 163, 167, 168
Non-keratinizing, squamous cell carcinoma, 266, 267, 316, 317
Non-medullary thyroid cancer, 355
Nuclear grooves, 86, 147

O

O6-Methylguanine DNA ethyltransferase (O6MGMT) 353
Ollier disease, 149
Oncocytic carcinoma, 43
Ordinary intraductal hyperplasia, 65
Osteosarcoma, 40, 97, 98, 101, 175, 188, 244, 246, 282
Ovarian tumour of probable wolffian origin, 186
Ovarian wolffian tumour, 182, 186

P

p14ARF, 353
p16/CDKN2a/p16INK4, 270, 353
p21, 250, 341, 348
p27, 58
p63, 86
p73, 362
Paget disease, 23, 35, 41, 63, 68, 105, 112, 174, 319, 321, 322, 324, 332, 352
Paget disease of the nipple, 35, 41, 105
Pagetoid spread, 332, 333
Paneth cell, 45, 125-127, 272, 276
Papillary adenoma, 104
Papillary carcinoma, non-invasive, 78
Papillary ductal carcinoma in situ, 79
Papillary hidradenoma, 321, 323
Papillary intraductal carcinoma, 32, 34, 79
Papillary squamous cell carcinoma, 267
Papilloma, 76-79, 119, 209, 296
Papillomatosis, 76, 104, 271, 296
Papillomatosis of the nipple, 104
Paraganglioma, 182, 187, 255, 283
Parasitic leiomyoma, 239
Parathyroid hormone-related protein, 138
Partial hydatidiform mole, 254
PAT1, 51
PDGFRL, 52
Peau d'orange, 48
PEComa, 243
Peptide YY, 172
Periductal stromal sarcoma, 100, 102
Peripheral papilloma, 76-78, 83
Peripheral primitive neuroectodermal tumour, 244, 255, 309, 334
Peritoneal mesothelioma, 185, 197, 199
Peritoneal mucinous carcinomatosis, 128
Peritoneal tumours, 197
Perivascular epithelioid cell tumour, 243
Peutz-Jeghers syndrome, 156-158, 208, 273
Pheochromocytoma, 187
Phosphoinositol-3-kinase, 357
Phyllodes tumour, 96, 97, 99-101, 103, 247, 352
Pigmented progonoma, 175
PIVKA-II (protein induced by vitamin K absence), 184
Placental alkaline phosphatase, 196

Placental site nodule, 211, 252, 254
 Placental site trophoblastic tumour, 210, 250-252
 Placental-like alkaline phosphatase (PLAP) 164, 168, 191, 252
 Plasma cell granuloma, 93
 Plasmacytoma, 192
 Pleomorphic adenoma, 41, 85, 86, 88, 307, 324
 Pleomorphic carcinoma, 21, 41
 Pleomorphic lobular carcinoma, 24, 25
 Plexiform leiomyoma, 241
 PMS1, 53, 360
 PMS2, 53, 359, 360
 PNET, *see* Primitive neuroectodermal tumour
 Polyembryoma, 163, 167, 168
 Polypoid adenofibroma, 209
 Polyvesicular vitelline tumour, 165
 Postmeiotic segregation 2, 359
 Postoperative spindle cell nodule, 244, 281, 283, 305, 326
 Post-radiotherapy angiosarcoma, 96
 Potter syndrome, 149
 Primary peritoneal borderline tumour, 197, 202
 Primary peritoneal carcinoma, 197, 201
 Primitive neuroectodermal tumour, 171, 174, 309, 310
 Proliferating trichilemmal tumour, 325
 Prophylactic bilateral mastectomy, 345
 Prophylactic bilateral salpingo-oophorectomy, 345
 Proteus syndrome, 357
 Protocadherin 9, 112
 Proximal-type epithelioid sarcoma, 326
 pS2, 72
 Psammocarcinoma, 201, 202
 Psammoma bodies, 68, 119, 122, 198, 202, 210, 214, 224, 225, 255, 274, 276
 Pseudoangiomatous hyperplasia, 103
 Pseudoangiomatous stromal hyperplasia, 90
 Pseudocarcinomatous hyperplasia, 209
 Pseudomyxoma ovarii, 129
 Pseudomyxoma peritonei, 126, 128, 129, 208
 PTEN, 131, 132, 145, 230-232, 318, 354-357, 359

R

Rad50, 341
 RAD51, 341-343, 348-351
 Radial scar, 26, 27, 39, 60, 78, 81-83
 Radial sclerosing lesion, 83
 RASSF1A (Ras association domain family 1A gene), 52
 RB1CC1 (RB1-inducible Coiled-Coil 1), 52
 Reichert membrane, 165
 Reifenstein syndrome, 112
 Reinke crystals, 154, 158, 160, 161, 176, 177
 Renin, 157, 207
 Rete cyst, 124
 Rete ovarii adenocarcinoma, 180
 Rete ovarii adenoma, 180
 Retiform Sertoli-Leydig cell tumour, 156
 Retiform wolffian adenocarcinoma, 212
 Retiform wolffian adenoma, 212
 Retiform wolffian tumour, 186
 Retinal anlage tumour, 171, 175
 Revised Amsterdam Criteria, 358
 Rhabdoid tumour, 244
 Rhabdomyoma, 244, 282, 305, 330
 Rhabdomyosarcoma, 40, 97, 101, 109, 135, 155, 175, 188, 244, 302, 309, 311, 326
 RING domain, 342
 Rokitsky protuberance, 163, 171
 RPS6KB1, 51

S

Salpingitis isthmica nodosa, 210
 Sarcoma botryoides, 155, 248, 280, 281, 283, 297, 302, 303, 305, 309, 326
 Sarcoma family syndrome of Li and Fraumeni, 351
 Schiller-Duval bodies, 165
 Schwannoma, 94, 283, 304, 330
 Scleroelastotic scar, 83
 Sclerosing adenosis, 27, 39, 60, 61, 78, 81-83, 86, 98, 99, 104
 Sclerosing papillary lesion, 39, 83
 Sclerosing papilloma, 77, 85, 104
 Sclerosing papillomatosis, 104
 Sclerosing peritonitis, 149, 150
 Sclerosing stromal tumour, 149, 152
 SCTAT, *see* Sex cord tumor with annular tubules

Sebaceous adenoma, 171, 175
 Sebaceous carcinoma, 37, 46, 47, 171, 175, 324
 Sebocrine cell, 47
 Seborrheic keratosis, 321
 Secretory carcinoma, 42
 Secretory variant, endometrioid adenocarcinoma, 130, 221, 223
 Seminoma, 163, 164, 176, 177
 Serotonin, 143, 173, 272, 279
 Serous adenocarcinoma, 119, 141, 201, 206, 212, 221, 224-226, 272, 274, 339
 Serous adenofibroma, 119
 Serous borderline adenofibroma, 122
 Serous borderline tumour, 119, 120, 121, 127, 144, 202, 209
 Serous borderline tumour with microinvasion, 120
 Serous cystadenoma, 119, 124, 209, 212
 Serous papillary cystadenoma, 119
 Serous psammocarcinoma, 119, 120
 Serous surface borderline tumour, 122
 Serous tumour of borderline malignancy, 120, 121
 Serous tumour of borderline malignancy with microinvasion, 120
 Serous tumour of low malignant potential with microinvasion, 120
 Serous tumour of low malignant potential, 121
 Sertoli cell tumour, 153, 156-159, 179, 196, 213
 Sertoli cell tumour, annular tubular variant, 158
 Sertoli-Leydig cell tumour, 131, 153, 157, 159, 172, 180, 188, 196, 213
 Sertoli-Leydig tumour with heterologous elements, 155
 Sex cord tumour with annular tubules, 157-159, 179, 273
 Sex hormone-binding globulin, 16
 Signet ring cell carcinoma, 30, 32, 42
 Signet-ring cell, 138, 272, 273
 Signet-ring cell adenocarcinoma, 193, 273
 Signet-ring stromal tumour, 153
 Simple atypical hyperplasia of the endometrium, 229
 Simple hyperplasia of the endometrium, 229
 Site specific early onset breast cancer syndrome, 346
 SIX1 homeobox gene, 72

Small cell / oat cell carcinoma, 32
 Small cell carcinoma, 32-34, 145, 148, 174, 182, 183, 196, 207, 221, 227, 266, 267, 277-279, 301, 309, 321, 323
 Small cell carcinoma of neuroendocrine type, 183, 227
 Small cell carcinoma hypercalcaemic type, 145, 182
 Small cell carcinoma, pulmonary type, 183
 Smooth muscle myosin, 75, 86
 Smooth muscle tumour of uncertain malignant potential, 238
 Solid neuroendocrine carcinoma, 32
 Spangaro bodies, 157
 Speckled penis, 357
 Spindle cell carcinoma, 37, 88, 92
 Spindle cell epithelioma, 307
 Spindle cell lipoma, 93
 Spindle cell variant, adenomyoepithelioma, 87
 Spindle cell variant, squamous cell carcinoma 38
 Squamotransitional carcinoma, 268
 Squamous intraepithelial lesion, 269, 270, 294
 Squamous papilloma, 266, 271, 272, 293, 296
 S-T syndrome, 95, 96
 ST7, 52
 Stellate scar, 83
 Sternberg tumour, 216
 Steroid cell tumour, 138, 160, 188, 196, 216
 Stewart Treves syndrome, 95
 STK11, 273
 STK15, 51
 Stromal hyperplasia, 189, 190
 Stromal hyperthecosis, 161, 189, 190
 Stromal luteoma, 160, 161
 Stromal polyp, 271, 297
 Stromal tumour with minor sex cord elements, 152
 Stromal-Leydig cell tumour, 158
 Struma ovarii, 138, 157, 160, 171, 172
 Strumal carcinoid, 171-173
 Subareolar duct papillomatosis, 104
 Superficial angiomyxoma, 327, 329
 Superficial spreading melanoma, 331
 Supernumerary ring chromosome, 327
 Sustentacular cell, 187
 Symplastic leiomyoma, 241

Synaptophysin, 30, 33, 34, 173, 279, 334
 Syncytial growth pattern, 28
 Syncytiotrophoblast, 164, 167, 168, 186, 207, 251, 252, 254
 Synovial sarcoma, 304, 307
 Syringoma, 81, 324, 325
 Syringomatous adenoma, 104, 105
 Syringomatous squamous tumour, 39

T

Tamoxifen-related lesions, 230
 TBX2, 51
 Terminal duct lobular unit (TDLU) 13, 17, 19, 60, 63, 66, 76, 79, 81
 Thecoma, 135, 147, 149, 150, 152, 158, 187, 215
 Thyroglobulin, 138, 172
 Thyroid transcription factor-1, 34
 TP53, *see* Li-Fraumeni syndrome
 TP73, 52, 352
 Transforming growth factor alpha, 58
 Transitional cell carcinoma, 140-142, 145, 174, 196, 206, 207, 226, 267, 268, 311, 321, 322, 339, 361
 Transitional cell metaplasia, 207, 268, 270, 295
 TRAP240, 51
 Trastuzumab, 58
 Trichilemmoma, 324, 325, 355
 Trichoepithelioma, 324, 325
 TTF-1 (thyroid transcription factor-1), 34
 Tubal epithelial hyperplasia, 209
 Tubular adenoma, 84, 87, 300
 Tubular carcinoma, 19, 23, 24, 26-28, 35, 73, 105, 336, 338, 356
 Tubulo-lobular carcinoma, 24, 346
 Tubulovillous adenoma, 300
 Tumour associated macrophages, 22
 Turcot syndrome, 360
 Turner syndrome, 176, 249

U

Ubiquitin ligase, 342
 Ubiquitin-mediated degradation, 53
 Ulex europaeus agglutinin-1, 91
 Unclassified sex cord-stromal tumour, 160
 Undifferentiated carcinoma of non-small cell neuroendocrine type, 184

Undifferentiated endocervical sarcoma, 280, 281
 Undifferentiated endometrial sarcoma, 233, 234, 236
 Undifferentiated ovarian sarcoma, 134, 135
 Undifferentiated uterine sarcoma, 236
 Undifferentiated vaginal sarcoma, 302, 303
 Uterus-like mass, 215

V

Vaginal intraepithelial neoplasia (VAIN), 293-296
 Vaginal micropapillomatosis, 296
 VATER, 357
 Verrucous carcinoma, 267, 294, 316, 317
 Vestibular micropapillomatosis, 320
 Vestibular papilloma, 316, 320
 VHL, *see* von-Hippel Lindau disease 214, 215
 Villoglandular variant, adenocarcinoma, 221, 223, 273
 Villous adenoma, 300
 VIN, *see* Vulvar intraepithelial neoplasia
 Virilization, 152, 156, 188-190
 von Hippel-Lindau disease, 212, 214, 215
 Vulvar intraepithelial neoplasia (VIN), 316, 318-320, 324

W

Walthard cell nests, 144
 Warty type, squamous cell carcinoma, 266, 267, 294, 316, 317
 Well differentiated papillary mesothelioma, 197, 198
 Wilms tumour, 169, 182, 187, 200, 256, 284, 285
 Wolffian adnexal tumour, 207, 212, 213, 215
 WT1, 200, 202

Y

Yolk sac tumour, 137, 138, 156, 163-166, 168, 170, 215, 246, 256, 287, 288, 309, 333

Z

ZNF217, 51
 Zymogen-like granule, 45